NEW YORK (Reuters) – Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, has settled all outstanding disputes with Retrophin Inc, the biopharmaceutical company he founded in 2011 and which ousted him three years later.
FILE PHOTO: Former drug company executive Martin Shkreli exits U.S. District Court after being convicted of securities fraud, in the Brooklyn borough of New York City, U.S., August 4, 2017. REUTERS/Carlo Allegri
A Retrophin spokeswoman said on Thursday that the accord covers Shkreli’s $30 million lawsuit last month accusing three former colleagues, including his successor as chief executive, of engineering his ouster and to enrich themselves from his work.
The settlement also covers claims Retrophin first raised in August 2015, in a $65 million lawsuit accusing Shkreli of repeatedly breaching his duty of loyalty to the San Diego-based company. That case moved to arbitration last year.
CNBC earlier reported the…